Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
Bioavailability: Overview01:13

Bioavailability: Overview

Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2026 Expert Consensus Recommendations on Hypertrophic Cardiomyopathy: A Report of the Task Force of the Taiwan Society of Cardiology.

Acta Cardiologica Sinica·2026
Same author

PCOS combined with obesity aggravates the metabolic and immune abnormality in females.

BMC women's health·2026
Same author

Proceedings of the 2024 FDA-CRCG Workshop: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products.

The AAPS journal·2026
Same author

Regio- and Diastereoselective Aminopyridylation of Bicyclo[1.1.0]butanes with <i>N</i>‑Aminopyridinium Ylides Enabled by Photoredox Catalysis.

Precision chemistry·2026
Same author

Biliary stenting combined with intraluminal 125 I seed brachytherapy versus biliary stenting alone for the treatment of cholangiocarcinoma: a meta-analysis.

International journal of surgery (London, England)·2025
Same author

An ingestible device for automated sampling and location tracing in gastrointestinal tract.

PloS one·2025

Related Experiment Video

Updated: Jun 2, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Using partial area for evaluation of bioavailability and bioequivalence.

Mei-Ling Chen1, Barbara Davit, Robert Lionberger

  • 1Office of Pharmaceutical Science Center for Drug Evaluation and Research Food and Drug Administration, 10903 New Hampshire Avenue, Building 51, Rm. 4108, Silver Spring, Maryland 20993-0002, USA. meiling.chen@fda.hhs.gov

Pharmaceutical Research
|April 14, 2011
PubMed
Summary
This summary is machine-generated.

The FDA recommends using early drug exposure metrics, like partial area under the curve (PAUC), for bioavailability and bioequivalence assessments. This approach offers greater sensitivity in detecting formulation differences compared to traditional peak concentration (Cmax) measures.

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products
14:54

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products

Published on: October 20, 2018

Related Experiment Videos

Last Updated: Jun 2, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products
14:54

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products

Published on: October 20, 2018

Area of Science:

  • Pharmacokinetics and Drug Development
  • Pharmaceutical Sciences

Background:

  • Traditional bioavailability/bioequivalence assessments rely on peak concentration (Cmax) and time to peak concentration (Tmax).
  • These parameters are indirect measures of drug absorption rate.
  • Systemic exposure is crucial for drug efficacy and safety.

Purpose of the Study:

  • To highlight the FDA's recommendation for enhanced bioavailability/bioequivalence assessment using systemic exposure.
  • To introduce and evaluate a new metric for early drug exposure.
  • To discuss the utility of partial area under the curve (PAUC) in assessing drug absorption.

Main Methods:

  • Comparison of traditional pharmacokinetic parameters (Cmax, Tmax) with early exposure metrics.
  • Introduction of partial area under the curve truncated at Tmax of the reference product (PAUC(r,tmax)) or a designated time.
  • Discussion of the application of reference-scaling for highly variable metrics.

Main Results:

  • Partial area under the curve (PAUC) provides a more sensitive measure of formulation differences than Cmax.
  • PAUC can be truncated at Tmax of the reference product or a specific early time point.
  • PAUC is valuable for pharmacokinetic/pharmacodynamic (PK/PD) characterization and bioequivalence evaluation.

Conclusions:

  • Early exposure metrics, specifically PAUC, offer improved sensitivity for bioavailability and bioequivalence studies.
  • The choice of truncation time for PAUC should be guided by PK/PD relationships or drug-specific data.
  • PAUC enhances the evaluation of drug comparability and characterization.